Core Viewpoint - The rapid rise and subsequent fall of Beilingsong and its founder Ma Xuejun illustrate the volatile nature of the capital market, where initial success can quickly turn into significant challenges and regulatory scrutiny [1][17]. Company Overview - Beilingsong, founded by Ma Xuejun, transitioned from a small health product company to a publicly listed entity on the STAR Market, achieving a market capitalization of over 100 billion yuan shortly after its IPO [7][10]. - The company initially focused on marketing, heavily investing in celebrity endorsements, which contributed to its rapid growth but also set the stage for future vulnerabilities [11][12]. Regulatory Issues - On December 25, 2025, Beilingsong announced that it and its actual controller Ma Xuejun were under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, leading to a 14.68% drop in stock price the following day [2][6]. - This was not the first time the company faced regulatory scrutiny; a self-inspection report revealed that Ma Xuejun had misappropriated 12.08 million yuan of company funds between 2021 and 2022 [4][5]. Financial Performance - Following its IPO, Beilingsong's financial performance deteriorated sharply, with a 24.7% decline in revenue in 2022, resulting in a net loss of 124 million yuan [13][14]. - Despite a revenue rebound to 1.275 billion yuan in 2023, the company continued to incur losses, with a projected net loss of 84 million to 105 million yuan for the entire year of 2025 [14][16]. Marketing Strategy - The company's aggressive marketing strategy, including high-profile endorsements from celebrities like Xiao Zhan and Yi Yang Qianxi, initially drove sales but later raised questions about sustainability and return on investment [11][12]. - Sales expenses remained disproportionately high, reaching 6.88 billion yuan in 2023, which accounted for 54% of revenue, indicating a troubling trend of high costs without corresponding revenue growth [14][16]. Challenges Ahead - As of early 2026, Beilingsong faced multiple challenges, including a significant drop in stock price (over 87% from its peak) and ongoing regulatory pressures [16]. - The company is attempting to pivot towards a new business model focused on "technology products + effective massage," but early results have shown a 34.07% decline in revenue for the first three quarters of 2025 [16].

Core Viewpoint - The company, Beilingsong (688793), is under investigation by the China Securities Regulatory Commission (CSRC) for alleged market manipulation by its actual controller, Ma Xuejun, which may impact investor confidence and market perception of the company [2][4]. Group 1: Investigation Details - On February 4, the company received a notice from the CSRC regarding the investigation of Ma Xuejun for suspected market manipulation [2]. - The investigation pertains solely to Ma Xuejun as an individual and is not expected to significantly affect the company's daily operations, with Ma continuing to fulfill his duties [4]. Group 2: Company Background - Beilingsong is a national high-tech enterprise that focuses on the innovation, research, and development of health products, primarily engaged in the design, production, and sales of smart portable massagers [4]. - The company went public on the Sci-Tech Innovation Board in 2021 [4]. Group 3: Financial Performance - The company anticipates a net loss for the fiscal year 2025, projecting a net profit attributable to shareholders of between -1.05 billion to -840 million [4]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -920 million to -710 million [4]. - The decline in revenue and profit is attributed to strategic adjustments in response to industry trends and market conditions, alongside increased fixed costs and ineffective sales expense management [5].

值得一提的是，在2025年12月底马学军刚遭到证监会立案调查。倍轻松2025年12月25日晚间披露公告显示， 因公司及马学军涉嫌信息披露违法违规，证监会决定对公司及马学军立案。这也意味着，不足一个半月马学 军两度遭到证监会立案。 资料显示，马学军1971年4月出生，2001年8月至今任倍轻松董事长、总经理，全面负责公司的经营管理。 实际上，除了公司及实控人遭立案的利空消息之外，倍轻松目前也面临不少"烦恼"。 被证监会立案不足一个半月，倍轻松（688793）实控人马学军又遭到了立案。2月5日晚间，倍轻松披露公告 称，公司于2月4日收到证监会对马学军下发的《立案告知书》，因其涉嫌操纵证券市场，证监会决定对其立 案。 倍轻松表示，本次调查事项系对马学军个人的调查，不会对公司的日常运营造成重大影响，其本人仍在公司 正常履职，目前公司各项经营活动和业务均正常开展。 对于公司业绩变动的原因，倍轻松表示，公司结合行业发展趋势及市场环境变化对经营战略进行阶段性调 整，受战略调整过渡期影响，报告期内营业收入较上年同期下降，进而带动毛利额下降；同时，经营端销售 费用投入产出效能未达预期，而固定支出和刚性成本短期内无法与营收规模实 ...

"便携按摩器第一股"倍轻松（688793.SH）业绩再陷亏损。 2026年1月28日，倍轻松发布2025年业绩预告，预计2025年度实现归属于母公司所有者的净利润为亏损 8400万元至1.05亿元，较上年同期的盈利1025.32万元由盈转亏；扣除非经常性损益后的净利润预计为亏 损7100万元至9200万元，较上年同期的亏损327.69万元，亏损同比扩大。 值得留意的是，2024年，倍轻松曾短暂扭亏，但公司预计2025年重回亏损。从历年财报数据来看，这将 是倍轻松自2021年上市以来的第三次陷入年度亏损。 《中国经营报》记者留意到，面对困境，倍轻松自2024年开始将线下直营店面从纯销售产品形态转变 为"科技产品+速效按摩"的新模式，并于2025年第二季度推出"轻松一刻"健康管理品牌，以"智能设备 +人工手法+艾灸理疗"形成三位一体的按摩服务体系。然而，这些变革成效仍有待释放。 在二级市场上，投资者正用脚投票。截至2026年1月30日收盘，倍轻松股价收于22.36元/股，市值仅剩 19.22亿元，较上市初期缩水超80%。从百亿元市值的明星企业到如今再陷亏损，倍轻松的转型之路依 然道阻且长。 面对千亿按摩市场业绩预 ...

Group 1 - The core viewpoint of the news is that Beilingsong (倍轻松) is experiencing a decline in both revenue and net profit, indicating potential challenges in its business performance [2] - As of January 29, Beilingsong's financing balance is 69.09 million yuan, accounting for 3.64% of its market capitalization, which is below the 40th percentile level over the past year, suggesting a low financing position [1] - The company reported a total revenue of 552 million yuan for the period from January to September 2025, a year-on-year decrease of 34.07%, and a net profit attributable to shareholders of -65.63 million yuan, a decrease of 600.98% year-on-year [2] Group 2 - Beilingsong has not distributed any dividends in the past three years, with a total payout of 66.94 million yuan since its A-share listing [3] - As of September 30, 2025, the number of shareholders increased by 4.92% to 5,073, while the average circulating shares per person decreased by 4.69% to 16,941 shares [2] - The company specializes in the research and development of health products, primarily focusing on the design, production, and sales of portable massage devices, with its main revenue sources being shoulder (22.03%), head and scalp (18.10%), and eye (13.08%) products [1]

Group 1 - The company announced a profit forecast indicating a return to losses in 2025, with expected net profit attributable to shareholders ranging from -105 million to -84 million yuan [1] - In 2024, the company reported a total profit of 11.83 million yuan, with a net profit attributable to shareholders of 10.25 million yuan, and a net profit excluding non-recurring gains and losses of -3.28 million yuan [1] - The company is undergoing a strategic adjustment due to changes in industry trends and market conditions, which has led to a decline in revenue and gross profit [1] Group 2 - Since its market debut in July 2021, the company's performance has shown significant volatility, with a 24.69% revenue decline in 2022 and a net profit loss of -124 million yuan [2] - Despite a revenue increase of over 40% in 2023, the company still reported a net profit loss of -50.87 million yuan [2] - The company specializes in the research and development of health products, particularly portable smart massagers, and is recognized as a national high-tech enterprise [3] Group 3 - The company and its actual controller are under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [3] - As of January 28, the company's stock price was 22.23 yuan per share, reflecting a decline of 1.98%, with a total market capitalization of 1.911 billion yuan [3]

据讯，曾被称作"智能按摩设备第一股"的倍轻松，在上个月扔出了一颗惊雷。 根据倍轻松发布的《关于收到中国证券监督管理委员会立案告知书的公告》显示，深圳市倍轻松科技股份有限公司及实控人马学军双双收到中国 证监会下发的立案告知书。 原因为 "涉嫌信息披露违法违规"！ 在公司管理上，公司创始人马学军自创立之初便担任董事长兼总经理，对公司拥有绝对控制权。 在公司近期业绩上，根据财报显示，倍轻松2025年上半年境外收入同比增速高达136.28%，2025年前三季，更是实现营业收入5.78亿元。 只是在这增收与应收的背后，净利润方面却出现了高达6562.80万元的亏损。 关于倍轻松 据了解，倍轻松成立于2000年，主营业务为智能便携按摩器的设计、研发与销售，公司于2021年7月登陆科创板，头顶"智能按摩设备第一股"光 环。 根据官方资料显示： 在产品上，倍轻松产品线涵盖头部、眼部、颈部等多个部位的智能便携按摩器，并以"融合中医理念与现代科技"为口号。 在渠道上，截至目前，倍轻松产品不但出口到全球数十个国家和地区，而且在国内外各大机场、高铁和shopping mall还已开设超180家直营店。 并且，近些年来，倍轻松还在不断 ...

Core Viewpoint - The stock price of Beilingsong has experienced fluctuations, with a recent decline of 2.03% and a total market value of 1.993 billion yuan, indicating potential investor concerns about the company's performance and market position [1]. Group 1: Stock Performance - Beilingsong's stock has increased by 6.38% year-to-date, but has seen a decline of 14.96% over the past 20 days and 20.14% over the past 60 days [2]. - As of January 9, the stock price is reported at 23.19 yuan per share, with a trading volume of 38.8463 million yuan and a turnover rate of 1.92% [1]. Group 2: Financial Performance - For the period from January to September 2025, Beilingsong reported a revenue of 552 million yuan, a year-on-year decrease of 34.07%, and a net profit attributable to shareholders of -65.628 million yuan, representing a significant decline of 600.98% [2]. - The company has not distributed any dividends in the past three years, with a total payout of 66.941 million yuan since its A-share listing [3]. Group 3: Company Overview - Beilingsong, established on July 5, 2000, and listed on July 15, 2021, is based in Shenzhen, Guangdong Province, and specializes in the innovation, research, and development of health products, particularly portable smart massagers [2]. - The company's revenue composition includes various segments: other products (24.24%), shoulder (22.03%), head and scalp (18.10%), eye (13.08%), back and waist (11.99%), and neck (10.57%) [2]. - Beilingsong is categorized under the household appliances industry, specifically in small appliances and personal care devices, and is associated with concepts such as micro-cap stocks, ByteDance, Tencent, artificial intelligence, and DeepSeek [2].

Company Overview - Shenzhen Beiliang Technology Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on July 5, 2000. The company went public on July 15, 2021. It focuses on the innovation, research, and development of health products, primarily engaged in the design, research, production, sales, and service of smart portable massagers [1]. Business Performance - As of January 6, the company's stock price decreased by 5.04%, reaching 23.72 CNY per share, with a trading volume of 64.6552 million CNY and a turnover rate of 3.10%. The total market capitalization is 2.039 billion CNY [1]. - The revenue composition of the company's main business includes: Other (24.24%), Shoulder (22.03%), Head + Scalp (18.10%), Eye (13.08%), Waist and Back (11.99%), and Neck (10.57%) [1]. Fund Holdings - According to data, one fund under Xinhua Fund holds a significant position in Beiliang. The Xinhua Small and Medium-sized Value Selection Mixed Fund (519097) held 27,600 shares in the third quarter, accounting for 1.28% of the fund's net value, making it the second-largest holding. The estimated floating loss today is approximately 34,800 CNY [2]. - The Xinhua Small and Medium-sized Value Selection Mixed Fund (519097) was established on January 28, 2011, with a latest scale of 64.4789 million CNY. Year-to-date returns are 1.09%, ranking 6060 out of 8816 in its category; the one-year return is 54.84%, ranking 1490 out of 8081; and since inception, the return is 368.71% [2]. Fund Management - The fund manager of the Xinhua Small and Medium-sized Value Selection Mixed Fund (519097) is Wang Yongming, who has been in the position for 8 years and 326 days. The total asset size of the fund is 331 million CNY. The best fund return during his tenure is 58.36%, while the worst return is -16.47% [3].

Core Viewpoint - The company,倍轻松, has experienced a significant decline in stock price and financial performance, indicating potential challenges in its business operations and market position [1][2]. Financial Performance - As of September 30, 2025, the company reported a revenue of 552 million yuan, a year-on-year decrease of 34.07% [2]. - The net profit attributable to shareholders was -65.628 million yuan, reflecting a substantial year-on-year decline of 600.98% [2]. - Cumulative cash dividends since the company's A-share listing amount to 66.941 million yuan, with no dividends paid in the last three years [3]. Stock Market Activity - On December 30, the stock price of 倍轻松 fell by 2.01%, trading at 21.94 yuan per share, with a total market capitalization of 1.886 billion yuan [1]. - The stock has declined by 26.38% year-to-date, with a 15.97% drop over the last five trading days and a 21.39% drop over the last 20 days [1]. - The company experienced a net outflow of 5.2368 million yuan in principal funds, with significant selling pressure observed [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 4.92% to 5,073, while the average circulating shares per person decreased by 4.69% to 16,941 shares [2][3]. - Among the top ten circulating shareholders, the 宝盈核心优势混合A fund holds 1.7 million shares, unchanged from the previous period [3]. Business Overview - 倍轻松, established on July 5, 2000, and listed on July 15, 2021, is a high-tech enterprise focused on the innovation, research, development, production, sales, and service of health products, particularly portable smart massagers [1]. - The company's revenue composition includes various product segments: 24.24% from other products, 22.03% from shoulder massagers, 18.10% from head and scalp massagers, 13.08% from eye massagers, 11.99% from waist and back massagers, and 10.57% from neck massagers [1].